News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New England Research Institutes Release: TOPCAT Study Shows Spironolactone Did Not Reduce Serious Cardiovascular Events


4/11/2014 8:14:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the inexpensive medication known as spironolactone to existing treatment does not significantly reduce the composite outcome from either death from cardiovascular causes, sudden cardiac arrest, or hospitalization to manage heart failure in patients with heart failure and a preserved ejection fraction, in a study funded by the National Heart, Lung and Blood Institute, National Institutes of Health.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES